Skip to main content
NASDAQ:SRPT

Sarepta Therapeutics Competitors

$75.13
-0.92 (-1.21 %)
(As of 05/17/2021 12:00 AM ET)
Add
Compare
Today's Range
$74.44
$76.22
50-Day Range
$69.38
$77.11
52-Week Range
$67.68
$181.83
Volume553,401 shs
Average Volume1.78 million shs
Market Capitalization$5.99 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.01

Competitors

Sarepta Therapeutics (NASDAQ:SRPT) Vs. CVAC, HZNP, CTLT, ELAN, ALNY, and ZLAB

Should you be buying SRPT stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Sarepta Therapeutics, including CureVac (CVAC), Horizon Therapeutics Public (HZNP), Catalent (CTLT), Elanco Animal Health (ELAN), Alnylam Pharmaceuticals (ALNY), and Zai Lab (ZLAB).

CureVac (NASDAQ:CVAC) and Sarepta Therapeutics (NASDAQ:SRPT) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, analyst recommendations, earnings and dividends.

Earnings & Valuation

This table compares CureVac and Sarepta Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CureVacN/AN/AN/AN/AN/A
Sarepta Therapeutics$380.83 million15.74$-715,080,000.00($9.71)-7.74

CureVac has higher earnings, but lower revenue than Sarepta Therapeutics.

Profitability

This table compares CureVac and Sarepta Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CureVacN/AN/AN/A
Sarepta Therapeutics-121.30%-61.62%-23.02%

Institutional & Insider Ownership

4.3% of CureVac shares are owned by institutional investors. Comparatively, 89.7% of Sarepta Therapeutics shares are owned by institutional investors. 5.9% of Sarepta Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for CureVac and Sarepta Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CureVac11302.40
Sarepta Therapeutics191302.52

CureVac currently has a consensus target price of $58.3333, indicating a potential downside of 49.88%. Sarepta Therapeutics has a consensus target price of $150.3810, indicating a potential upside of 100.16%. Given Sarepta Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Sarepta Therapeutics is more favorable than CureVac.

Summary

Sarepta Therapeutics beats CureVac on 6 of the 9 factors compared between the two stocks.

Horizon Therapeutics Public (NASDAQ:HZNP) and Sarepta Therapeutics (NASDAQ:SRPT) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends and profitability.

Earnings and Valuation

This table compares Horizon Therapeutics Public and Sarepta Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Horizon Therapeutics Public$1.30 billion16.22$573.02 million$1.9448.35
Sarepta Therapeutics$380.83 million15.74$-715,080,000.00($9.71)-7.74

Horizon Therapeutics Public has higher revenue and earnings than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Horizon Therapeutics Public, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Horizon Therapeutics Public and Sarepta Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Horizon Therapeutics Public43.55%25.66%14.19%
Sarepta Therapeutics-121.30%-61.62%-23.02%

Institutional & Insider Ownership

88.6% of Horizon Therapeutics Public shares are owned by institutional investors. Comparatively, 89.7% of Sarepta Therapeutics shares are owned by institutional investors. 4.3% of Horizon Therapeutics Public shares are owned by insiders. Comparatively, 5.9% of Sarepta Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

Horizon Therapeutics Public has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Comparatively, Sarepta Therapeutics has a beta of 2.01, suggesting that its share price is 101% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings for Horizon Therapeutics Public and Sarepta Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Horizon Therapeutics Public001103.00
Sarepta Therapeutics191302.52

Horizon Therapeutics Public currently has a consensus price target of $111.3636, indicating a potential upside of 18.74%. Sarepta Therapeutics has a consensus price target of $150.3810, indicating a potential upside of 100.16%. Given Sarepta Therapeutics' higher probable upside, analysts plainly believe Sarepta Therapeutics is more favorable than Horizon Therapeutics Public.

Summary

Horizon Therapeutics Public beats Sarepta Therapeutics on 9 of the 14 factors compared between the two stocks.

Catalent (NYSE:CTLT) and Sarepta Therapeutics (NASDAQ:SRPT) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends and profitability.

Earnings and Valuation

This table compares Catalent and Sarepta Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Catalent$3.09 billion5.62$173 million$1.8854.27
Sarepta Therapeutics$380.83 million15.74$-715,080,000.00($9.71)-7.74

Catalent has higher revenue and earnings than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Catalent, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Catalent and Sarepta Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Catalent9.25%14.20%4.83%
Sarepta Therapeutics-121.30%-61.62%-23.02%

Institutional & Insider Ownership

97.8% of Catalent shares are owned by institutional investors. Comparatively, 89.7% of Sarepta Therapeutics shares are owned by institutional investors. 1.0% of Catalent shares are owned by insiders. Comparatively, 5.9% of Sarepta Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

Catalent has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500. Comparatively, Sarepta Therapeutics has a beta of 2.01, suggesting that its share price is 101% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings for Catalent and Sarepta Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Catalent01702.88
Sarepta Therapeutics191302.52

Catalent currently has a consensus price target of $125.1250, indicating a potential upside of 22.65%. Sarepta Therapeutics has a consensus price target of $150.3810, indicating a potential upside of 100.16%. Given Sarepta Therapeutics' higher probable upside, analysts plainly believe Sarepta Therapeutics is more favorable than Catalent.

Summary

Catalent beats Sarepta Therapeutics on 9 of the 14 factors compared between the two stocks.

Elanco Animal Health (NYSE:ELAN) and Sarepta Therapeutics (NASDAQ:SRPT) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends and profitability.

Earnings and Valuation

This table compares Elanco Animal Health and Sarepta Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Elanco Animal Health$3.07 billion5.39$67.90 million$1.0633.03
Sarepta Therapeutics$380.83 million15.74$-715,080,000.00($9.71)-7.74

Elanco Animal Health has higher revenue and earnings than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Elanco Animal Health and Sarepta Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Elanco Animal Health-8.45%3.43%2.04%
Sarepta Therapeutics-121.30%-61.62%-23.02%

Institutional & Insider Ownership

86.8% of Elanco Animal Health shares are owned by institutional investors. Comparatively, 89.7% of Sarepta Therapeutics shares are owned by institutional investors. 0.1% of Elanco Animal Health shares are owned by insiders. Comparatively, 5.9% of Sarepta Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

Elanco Animal Health has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500. Comparatively, Sarepta Therapeutics has a beta of 2.01, suggesting that its share price is 101% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings for Elanco Animal Health and Sarepta Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Elanco Animal Health13902.62
Sarepta Therapeutics191302.52

Elanco Animal Health currently has a consensus price target of $33.1364, indicating a potential downside of 5.35%. Sarepta Therapeutics has a consensus price target of $150.3810, indicating a potential upside of 100.16%. Given Sarepta Therapeutics' higher probable upside, analysts plainly believe Sarepta Therapeutics is more favorable than Elanco Animal Health.

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Sarepta Therapeutics (NASDAQ:SRPT) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends and profitability.

Analyst Ratings

This is a breakdown of recent ratings for Alnylam Pharmaceuticals and Sarepta Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Alnylam Pharmaceuticals08802.50
Sarepta Therapeutics191302.52

Alnylam Pharmaceuticals currently has a consensus price target of $168.7333, indicating a potential upside of 24.17%. Sarepta Therapeutics has a consensus price target of $150.3810, indicating a potential upside of 100.16%. Given Sarepta Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Sarepta Therapeutics is more favorable than Alnylam Pharmaceuticals.

Risk and Volatility

Alnylam Pharmaceuticals has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500. Comparatively, Sarepta Therapeutics has a beta of 2.01, suggesting that its share price is 101% more volatile than the S&P 500.

Earnings and Valuation

This table compares Alnylam Pharmaceuticals and Sarepta Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alnylam Pharmaceuticals$219.75 million72.69$-886,120,000.00($8.11)-16.76
Sarepta Therapeutics$380.83 million15.74$-715,080,000.00($9.71)-7.74

Sarepta Therapeutics has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Alnylam Pharmaceuticals and Sarepta Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Alnylam Pharmaceuticals-222.19%-65.96%-31.38%
Sarepta Therapeutics-121.30%-61.62%-23.02%

Institutional & Insider Ownership

92.4% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 89.7% of Sarepta Therapeutics shares are owned by institutional investors. 3.5% of Alnylam Pharmaceuticals shares are owned by insiders. Comparatively, 5.9% of Sarepta Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Sarepta Therapeutics beats Alnylam Pharmaceuticals on 11 of the 14 factors compared between the two stocks.

Sarepta Therapeutics (NASDAQ:SRPT) and Zai Lab (NASDAQ:ZLAB) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, dividends, profitability and risk.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Sarepta Therapeutics and Zai Lab, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sarepta Therapeutics191302.52
Zai Lab00503.00

Sarepta Therapeutics presently has a consensus price target of $150.3810, indicating a potential upside of 100.16%. Zai Lab has a consensus price target of $197.8460, indicating a potential upside of 28.48%. Given Sarepta Therapeutics' higher probable upside, equities analysts clearly believe Sarepta Therapeutics is more favorable than Zai Lab.

Risk and Volatility

Sarepta Therapeutics has a beta of 2.01, suggesting that its stock price is 101% more volatile than the S&P 500. Comparatively, Zai Lab has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500.

Earnings & Valuation

This table compares Sarepta Therapeutics and Zai Lab's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sarepta Therapeutics$380.83 million15.74$-715,080,000.00($9.71)-7.74
Zai Lab$12.98 million1,123.31$-195,070,000.00($3.03)-50.82

Zai Lab has lower revenue, but higher earnings than Sarepta Therapeutics. Zai Lab is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Sarepta Therapeutics and Zai Lab's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sarepta Therapeutics-121.30%-61.62%-23.02%
Zai LabN/AN/AN/A

Institutional and Insider Ownership

89.7% of Sarepta Therapeutics shares are owned by institutional investors. Comparatively, 81.3% of Zai Lab shares are owned by institutional investors. 5.9% of Sarepta Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.


Sarepta Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
CureVac logo
CVAC
CureVac
0.7$116.38-5.5%$21.75 billionN/A0.00
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.4$93.79-1.8%$21.08 billion$1.30 billion25.63Insider Selling
Catalent logo
CTLT
Catalent
1.7$102.02-0.7%$17.38 billion$3.09 billion64.98Analyst Revision
Elanco Animal Health logo
ELAN
Elanco Animal Health
1.9$35.01-0.6%$16.56 billion$3.07 billion-61.42Analyst Report
Analyst Revision
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.6$135.89-0.1%$15.97 billion$219.75 million-17.36Insider Selling
Zai Lab logo
ZLAB
Zai Lab
1.6$153.99-0.7%$14.58 billion$12.98 million-50.82Earnings Announcement
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
2.1$77.34-0.5%$14.13 billion$1.70 billion17.70
Grifols logo
GRFS
Grifols
1.3$18.69-0.3%$12.85 billion$5.71 billion16.69Analyst Upgrade
News Coverage
Dr. Reddy's Laboratories logo
RDY
Dr. Reddy's Laboratories
1.3$72.00-0.0%$11.97 billion$2.32 billion59.50Earnings Announcement
Analyst Report
Teva Pharmaceutical Industries logo
TEVA
Teva Pharmaceutical Industries
1.4$10.76-1.8%$11.75 billion$16.89 billion-2.92
Bausch Health Companies logo
BHC
Bausch Health Companies
1.9$29.25-0.6%$10.48 billion$8.60 billion-5.37
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
1.9$176.80-1.3%$10.06 billion$2.16 billion55.77Analyst Report
Maravai LifeSciences logo
MRVI
Maravai LifeSciences
1.5$38.40-1.2%$9.89 billionN/A0.00Earnings Announcement
Analyst Report
Lockup Expiration
Analyst Revision
United Therapeutics logo
UTHR
United Therapeutics
1.5$198.29-0.2%$8.88 billion$1.45 billion18.76
BridgeBio Pharma logo
BBIO
BridgeBio Pharma
2.0$54.13-0.9%$8.08 billion$40.56 million-15.87
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.6$155.50-0.7%$8.00 billion$3.34 million-20.19Analyst Upgrade
Analyst Revision
News Coverage
Gap Down
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.3$73.05-0.3%$7.60 billion$87.99 million-86.96
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.7$110.29-0.5%$7.44 billion$103.71 million-25.12
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$135.63-2.5%$7.29 billion$14.98 million-16.52Upcoming Earnings
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.3$218.96-0.0%$6.86 billion$311.33 million-127.30
Perrigo logo
PRGO
Perrigo
2.2$45.46-0.9%$6.07 billion$4.84 billion-757.54Earnings Announcement
Analyst Revision
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$93.88-2.7%$5.48 billion$66.51 million17.32Insider Selling
Allakos logo
ALLK
Allakos
1.7$100.54-0.1%$5.39 billionN/A-36.69Analyst Downgrade
Analyst Revision
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$37.32-2.5%$5.26 billion$1.12 billion77.75Analyst Report
Galapagos logo
GLPG
Galapagos
1.3$77.00-1.1%$5.04 billion$1.00 billion-11.67Analyst Report
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$33.85-1.2%$4.79 billion$150,000.00-15.97Earnings Announcement
Analyst Revision
I-Mab logo
IMAB
I-Mab
1.2$63.60-2.0%$4.60 billion$4.31 million-2.20News Coverage
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$70.27-0.6%$4.57 billionN/A-5.73Analyst Report
Schrödinger logo
SDGR
Schrödinger
1.6$61.45-0.3%$4.30 billion$85.54 million0.00Insider Selling
Analyst Revision
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$53.06-16.6%$4.27 billionN/A-7.15Analyst Report
Unusual Options Activity
News Coverage
Gap Up
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$72.75-2.6%$4.25 billion$6.87 million-7.03
LEGN
Legend Biotech
1.3$30.90-4.2%$4.11 billion$64.39 million0.00Analyst Report
High Trading Volume
News Coverage
Gap Up
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$26.75-3.5%$3.98 billion$204.89 million-33.44
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$60.89-0.9%$3.70 billion$806.43 million-8.62
Alkermes logo
ALKS
Alkermes
1.2$22.08-0.8%$3.54 billion$1.17 billion-48.00
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$70.45-1.6%$3.46 billionN/A-20.07
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.5$55.72-0.9%$3.43 billion$117.91 million-11.30
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.23-2.5%$3.40 billion$339.08 million-12.34Analyst Revision
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$18.19-4.3%$3.32 billion$114.62 million-7.33Analyst Report
Insider Selling
Arvinas logo
ARVN
Arvinas
1.7$67.24-0.5%$3.29 billion$42.98 million-26.27
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$110.73-2.8%$3.26 billionN/A-55.09
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.2$60.29-2.8%$3.23 billion$1.11 billion19.39
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$37.10-1.3%$3.01 billion$60,000.00-11.52Analyst Upgrade
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$79.07-0.9%$2.86 billion$26.52 million-6.97
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$73.29-0.9%$2.80 billion$644.77 million-10.46Upcoming Earnings
MorphoSys logo
MOR
MorphoSys
0.3$20.93-0.1%$2.75 billion$80.43 million99.67
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.3$61.60-1.0%$2.71 billion$421.03 million21.69Analyst Report
Insmed logo
INSM
Insmed
1.2$26.04-0.7%$2.69 billion$136.47 million-10.02Analyst Report
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.5$38.00-0.0%$2.68 billion$306.98 million-5.44Analyst Report
News Coverage
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$40.40-1.3%$2.56 billionN/A-22.20Earnings Announcement
Analyst Revision
This page was last updated on 5/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.